Navigation Links
Study first to pinpoint why analgesic drugs may be less potent in females than in males
Date:12/23/2008

n. Interestingly, when they used a plant-derived toxin to remove the mu-opioid receptor from the PAG, morphine no longer worked, suggesting that this brain region is required for opiate-mediated pain relief.

Additional tests also found females reacted differently to morphine depending on the stage of their estrous cycle. These findings indicate that steroid hormones may affect mu-opioid receptor levels in the region of the PAG that are essential for analgesia and also suggest that the actions of morphine are estrous stage-dependent.

"Interestingly, sex is not the only factor that has been shown to affect the potency of various pharmacological agents. Recent studies have reported an influence of age and ethnicity, and further argue for the inclusion of a wide range of study subjects in pain management research," Murphy said. "In addition, despite the rapidly mounting evidence regarding the limitations of opiates in treating persistent pain, opioid-based drugs remain the primary pharmacological tool for pain management. Clearly additional research with the inclusion of female subjects needs to be devoted to determining a more potent treatment for persistent pain in women."


'/>"/>

Contact: Martha Barker Koontz
mbarker@gsu.edu
404-413-5464
Georgia State University
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Study links ecosystem changes in temperate lakes to climate warming
2. New edition of laboratory manual includes cutting-edge techniques to study gene regulation
3. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
4. Scientists study how asbestos fibers trigger cancer in human cells
5. Male dinosaurs may have been prehistoric babysitters, study shows
6. Study: Did early climate impact divert a new glacial age?
7. Purdue study suggests warmer temperatures could lead to a boom in corn pests
8. Study links ecosystem changes in temperate lakes to climate warming
9. Study of placenta unexpectedly leads to cancer gene
10. New study pardons the misunderstood egg
11. Ocean fish farming harms wild fish, study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How nutrition affects healthy aging 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3VA Honors Eye Researchers With Olin Teague Award 58162 1VA Honors Eye Researchers With Olin Teague Award 58162 2ReBuilder Medical Technologies Inc Announces Medicare Billing Ability for its ReBuilder Product 58157 1ReBuilder Medical Technologies Inc Announces Medicare Billing Ability for its ReBuilder Product 58157 2Food Addicts Convention Draws 800 Members from 31 States 5 Nations Around the World 58152 1Food Addicts Convention Draws 800 Members from 31 States 5 Nations Around the World 58152 2Food Addicts Convention Draws 800 Members from 31 States 5 Nations Around the World 58152 3
...ring atomic blast shook the Pacific atoll of Bikin...ecies, however, appear to be locally extinct. , T...n by an international team of scientists from Aust...ands. The expedition examined the diversity and a...the most interesting aspects is that the team dive...
...ts Medical School professor of molecular medicine ...s (mRNAs)opened a dramatic new world of investigat...008 Gairdner International Award, considered one o...es the award with collaborator Gary Ruvkun, PhD, p...th whom he discovered micro miRNAs. Ambros will be...
... Applications, Live Face Detection and Incorpora... Biometric Identification, VILNIU...Neurotechnologija), a provider of high-precision b...ced the availability of two new biometric,software...int recognition,and VeriLook 3.2 SDK for facial re...
Other Biology News:Bikini corals recover from atomic blast 2Bikini corals recover from atomic blast 3UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 2UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 3VeriFinger 6.0 SDK for Fingerprint Recognition and VeriLook 3.2 SDK for Facial Recognition are Now Available 2VeriFinger 6.0 SDK for Fingerprint Recognition and VeriLook 3.2 SDK for Facial Recognition are Now Available 3
(Date:12/4/2009)CORALVILLE, Iowa, Dec. 4 Vivakor, Inc. (OTC Bulletin Board: VIVK) today confirmed that its shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmer
(Date:12/3/2009)HOUSTON, Dec. 3 JourneyLite of Houston, LLC announced today that it has updated its facility to offer patients a second surgical option, vertical sleeve gastrectomy , along with the LAP-BAND®
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
Breaking Biology Technology:Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3
... 1 VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ), a b...,compounds for the treatment of cardiovascular dis...A,s senior vice president of research and,developm...nces Drug,Discovery & Development of Innovative Th...in Boston, MA., The presentation details are as ...
...Due to its remarkable electronic properties, few l...new material for use in post-silicon devices that ... nanoscale. Now, physicists at the University of ...ch FLG can be etched along flawless, crystallograp...s, a technique that results in atomically precise,...
...ows 15 Percent Quarter-over-Quarter -, PALO ALTO,...VTX ) today reported financial results for the sec... ended June 30, 2008, the Company reported a net l...ares to a net loss of $31.9,million, or $0.53 per ...and,$57.6 million, or $0.97 per share, for the sam...
Other Biology Technology:VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress 2Penn scientists carve functional nanoribbons using super-heated, nano-sized particles of iron 2CV Therapeutics Reports 2008 Second Quarter Financial Results 2CV Therapeutics Reports 2008 Second Quarter Financial Results 3CV Therapeutics Reports 2008 Second Quarter Financial Results 4CV Therapeutics Reports 2008 Second Quarter Financial Results 5CV Therapeutics Reports 2008 Second Quarter Financial Results 6CV Therapeutics Reports 2008 Second Quarter Financial Results 7
Anti-IRF7 Polyclonal Antibody, Unconjugated from Invitrogen
GoTaq Flexi DNA Polymerase from Promega
Rabbit Anti-Human EMBP Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Rabbit Anti-T-box 6 Monoclonal Antibody, Unconjugated, Clone PADZMD.501 from Invitrogen
Biology Products: